Published by Peptide Protocols · Reviewed September 2026 · How we make these pages · Educational & research purposes only — not medical advice.
For years, the GLP-1 conversation came with a catch: to get the big-name benefits, you generally had to make friends with a needle. Orforglipron changes that part of the story. In April 2026 the FDA approved orforglipron (brand name Foundayo) — the first oral GLP-1 for weight management that you can take any time of day, with no food or water restrictions. Needles finally have competition, and they are not taking it well.
Orforglipron is a once-daily pill that activates the same GLP-1 receptor as the injectables everyone's been talking about — but it's built differently. Technically it's a non-peptide small molecule, which is a nerdy way of saying it's sturdy enough to survive your stomach and get absorbed without the elaborate timing rituals older oral options required.
In head-to-head research, orforglipron outperformed oral semaglutide for blood-sugar control and weight — and Lilly is pursuing a type-2-diabetes indication too, based on its Phase-3 ACHIEVE program.
For the deeper family tree — including the next-gen dual and triple agonists — see tirzepatide vs semaglutide and retatrutide, the triple-G peptide.
And the one we bang the drum about constantly: appetite suppression strong enough to move the scale can quietly cost you lean muscle if protein and resistance training don't come along for the ride. Losing weight is the goal; losing your muscle is a tax nobody mentions at signup. That's the whole reason our GLP-1 muscle-preservation guide exists.
Vial mg + bacteriostatic water mL + your target mcg → mL and U-100 syringe units, instantly. Free, no sign-up, 60+ research peptides preset — plus dedicated calculators and BAC-water charts for BPC-157, retatrutide, tirzepatide, semaglutide, tesamorelin and CJC-1295/ipamorelin.
Open the free peptide calculator →Research & educational use only — never medical advice.
Pricing varies a lot by insurance and program. Publicly reported figures at launch ranged from as little as ~$25/month with a commercial savings card to ~$149/month self-pay for the lowest dose. Translation: check your actual coverage before you assume anything — the sticker and the out-of-pocket are rarely the same number.
Yes — the FDA approved it (as Foundayo) in April 2026 for weight management, with a diabetes application in progress.
No — it's a non-peptide small molecule that acts on the GLP-1 receptor. Same target, different chemistry, which is what lets it work as a simple daily pill.
In research it lowered A1C and body weight, and beat oral semaglutide in comparisons. Individual results and the right choice for any person are clinical decisions — not something a guide can promise.
Yes. It's a GLP-1, so the ‘protect your muscle with protein + resistance training’ rule applies exactly the same.
The Universal Logbook and reconstitution tools keep your notes clean and the math done for you across any compound you study.
Browse the shop on Etsy →We do not recommend or partner with any peptide supplier. Use the checklist instead: third-party COAs that match your batch and lot, stated purity, clear research-use labeling, real support and proper cold-chain shipping.
The supplier checklist →Educational content only. Confirm the legal status where you live before ordering anything.
The one formula, a BAC-water chart, and the 10 most-researched beginner peptides — the math done for you. Print it for the fridge.
🎁 Send me the free cheat sheet →